Commercial support and bias in pharmaceutical research

American Journal of Medicine

Volumn 117, Issue 11, 2004, Pages 876-878

  Landefeld, C Seth ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b 3333 California St S F ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMMERCIAL PHENOMENA; DRUG INDUSTRY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; INFORMATION DISSEMINATION; MEDICAL PROFESSION; MEDICAL RESEARCH; MEDICAL SOCIETY; PRIORITY JOURNAL;

CAPITAL FINANCING; DRUG INDUSTRY; PHARMACOLOGY; PREJUDICE; RESEARCH; RESEARCH SUPPORT; UNITED STATES;

EID: 10044269838     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2004.10.001     Document Type: Editorial

References (23)

1. T.E. Finucane, C.E. Boult Association of funding and findings of pharmaceutical research at a meeting of a medical professional society Am J Med 117 2004 842 845
2. J. Lexchin, L.A. Bero, B. Djulbegovic, O. Clark Pharmaceutical industry sponsorship and research outcome and quality systematic review BMJ 326 2003 1167 1170
3. J.E. Bekelman, Y. Li, C.P. Gross Scope and impact of financial conflicts of interest in biomedical research a systematic review JAMA 289 2003 454 465
4. R.A. Davidson Source of funding and outcome of clinical trials J Gen Intern Med 1 1986 155 158
5. J. Yaphe, R. Edman, B. Knishkowy, J. Herman The association between funding by commercial interests and study outcome in randomized controlled drug trials Fam Pract 18 2001 565 568
6. M. Friedberg, B. Saffran, T.J. Stinson, W. Nelson, C.L. Bennett Evaluation of conflict of interest in economic analyses of new drugs used in oncology JAMA 282 1999 1453 1457 20
7. B. Djulbegovic, M. Lacevic, A. Cantor, K.K. Fields, C.L. Bennett, J.R. Adams, N.M. Kuderer, G.H. Lyman The uncertainty principle and industry-sponsored research Lancet 356 2000 635 638
8. H. Melander, J. Ahlqvist-Rastad, G. Meijer, B. Beermann Evidence b(i)ased medicineselective reporting from studies sponsored by pharmaceutical industry review of studies in new drug applications BMJ 326 2003 1171 1173
9. M. Bhandari, J.W. Busse, D. Jackowski, V.M. Montori, H. Schunemann, S. Sprague, D. Mears, E.H. Schemitsch, D. Heels-Ansdell, P.J. Devereaux Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials CMAJ 170 2004 477 480
10. B. Als-Nielsen, W. Chen, C. Gluud, L.L. Kjaergard Association of funding and conclusions in randomized drug trials a reflection of treatment effect or adverse events? JAMA 290 2003 921 928
11. L.A. Bero, D. Rennie Influences on the quality of published drug studies Int J Technol Assess Health Care 12 1996 209 237
12. M.G. Ziegler, P. Lew, B.C. Singer The accuracy of drug information from pharmaceutical sales representatives JAMA 273 1995 1296 1298
13. C.D. Furberg, M.A. Hall, M.A. Sevick Balancing commercial and public interests Curr Control Trials Cardiovasc Med 5 2004 6
14. The truth is out there Lancet Neurology 2 2003 261
15. S.L. Coyle Physician-industry relations. Part 2: organizational issues Ann Intern Med 136 2002 403 406
16. M.A. Rodwin Physicians' conflicts of interest. The limitations of disclosure N Engl J Med 321 1989 1405 1408
17. J. Dana, G. Loewenstein A social science perspective on gifts to physicians from industry JAMA 290 2003 252 255
18. A. Schafer Biomedical conflicts of interest a defense of the sequestration thesislearning from the cases of Nancy Olivieri and David Healy J Med Ethics 30 2004 8 24
19. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 283 2000 1967 1975
20. S. Hulley, D. Grady, T. Bush Heart and Estrogen/progestin Replacement Study Research Group Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women JAMA 280 1998 605 613
21. B.W. Forsyth, R.I. Horwitz, D. Acampora New epidemiologic evidence confirming that bias does not explain the aspirin/Reye's syndrome association JAMA 261 1989 2517 2524
22. M.M. Chren Independent investigators and for-profit companies Arch Dermatol 130 1994 432 437
23. R. Moynihan Who pays for the pizza? Redefining the relationships between doctors and drug companies. 2: Disentanglement BMJ 326 2003 1193 1196